Oncocit: International Leader in Biotechnology for Personalized and Precision Immunotherapy in Cancer
Oncocit: A Leader in Advanced Immunotherapy and Oncology Biotechnology
Oncocit is a leader in advanced immunotherapy, specializing in the development of ready-to-use bioinputs and biotechnological kits designed for personalized cancer treatments. Our innovation focuses on cutting-edge technologies, such as enriched exosomes and optimized protocols, which offer highly accurate, safe and accessible scientific solutions.
With more than 10 years of experience, our work has been validated through government-funded projects, university collaborations, technology transfer, indexed publications and presentations at prestigious international conferences. Oncocit is committed to transforming immuno-oncology, significantly improving the quality of life of patients and setting a new personalized standard in cancer treatment.
ONCOCIT maintains selective coverage with former clients for the following complementary services, subject to feasibility and demand: • Patient consultation and guidance: In international immuno-oncology programs, including after-sales service. • Development of specific bibliography: For the guidance and education of cancer patients. • Online dissemination of scientific events: Courses, congresses and international meetings organized by centers, institutes and laboratories. • Monitoring and validation of patient progress: Under RECIST criteria, including translation of exams and obtaining testimonials.
Revolutionizing Access to Oncology Biotechnology
Oncocit is establishing itself as a global benchmark in precision biotechnology, developing customized biotechnological inputs and implementation protocols that allow oncology centers and healthcare professionals to offer innovative solutions in immunotherapy. Through the Contract Development and Manufacturing Organization (CDMO) model, we facilitate access to advanced technologies, especially for those seeking to implement research in immunotherapy with dendritic cells and exosomes.
Ready-to-Use Kits for Advanced Therapies One of Oncocit’s main achievements is the provision of ready-to-use kits, designed to simplify the implementation of advanced protocols such as immunotherapy with pulsed dendritic cells and derived exosomes. These supplies allow cancer centers, even those with limited resources, to develop lines of research and clinical translation without the need for expensive equipment or complex infrastructure.
Learn more
Innovation in Inputs
Learn more
Benefits for Cancer Centers and Clinics
Facilitating Immunotherapy Research and Development Oncocit offers cancer centers the opportunity to diversify their therapeutic approach with customized solutions, allowing professionals to develop immunotherapy research protocols and carry out clinical translation. This contributes to attracting new patients looking for innovative and effective options.
Ongoing Collaboration for Success Our team of experts is committed to providing advice and support to each partner corporation. From implementing protocols to training staff, we ensure our clients are fully equipped to maximize the impact of our inputs on patient care.
Learn more
Consulting and Comprehensive Support
Learn more
A Promising Future in Biotechnology
Leading Innovation in Immunotherapy Oncocit is not only focused on the present, but also looks to the future. With expansion plans in Europe and Asia, we are constantly developing new technologies that position Oncocit as a leader in oncology treatment globally. Our biotechnological inputs are the foundation for the future of immunotherapy.
Quality Control and Scientific Validation
Rigorous Protocols to Ensure Efficacy Oncocit’s theranostic kits undergo strict quality controls that ensure their efficacy and safety in clinical settings. Cell viability is assessed using flow cytometry, an advanced method that allows determining the number of viable cells in a sample, ensuring that the inputs maintain their functionality. The immunological potency of the kits is determined through cytokine release studies, where TH1, TH2 and TH17 immune profiles are analyzed. This characterization provides critical information on the induced immune response, ensuring that the inputs are capable of adequately activating the patient’s immune system.
Furthermore, the structural integrity of the exosomes is verified by Western blot analysis, a method that allows the detection and quantification of specific proteins, such as CD80, CD83 and HLA-DR, which are crucial markers for the characterization of exosomes in therapeutic contexts. The characterization of the exosomes is performed using Nanosight technology, which provides nanoparticle analysis to determine the size and concentration of the exosomes, ensuring that they meet the highest standards of quality and efficacy. These scientific methods, combined, ensure that Oncocit can offer biotechnological inputs that not only meet, but exceed expectations of quality and effectiveness in advanced oncological treatments
Learn more
We are the International Program of Advanced Immunotherapy With more testimonials
Cancer Patient Testimony: DEXs Immunotherapy Program by Oncocit Cancer Network Success Stories in Cancer Treatment.
- Cure or Complete Remission: Patients who achieve complete cure or total remission of their cancer. (Hodi et al., 2018).
- Partial Remission: Significantly reducing tumor burden. (Chiou & Burotto, 201
- No Progression or Tumor Stability: Maintaining stable disease without progression despite the time elapsed. (Wolchok et al., 2009).
- Reduction in Tumor Metabolic Activity (SUV) or Lesion Size: Decrease in tumor metabolic activity or a reduction in lesion size. (Wahl et al., 2009).
- Improved Clinical Condition Despite Tumor Progression: Patients report improvement in their general clinical condition, even if the tumor continues to progress. (Cleeland et al., 2000).
- Clinical Stabilization Allowed for New Therapies: Patients manage to stabilize their clinical condition enough to be admitted to conventional therapies that had previously been ruled out. (Otter et al., 2019).
Overcoming Resistance to Conventional Therapies: Avoiding relapse or non-response to conventional therapies, opening up new therapeutic options. (Sachpekidis et al., 2019).